OncoMatch/Clinical Trials/NCT06644781
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Is NCT06644781 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Docetaxel for esophageal squamous cell carcinoma.
Treatment: Ifinatamab deruxtecan · Docetaxel · Paclitaxel · Irinotecan hydrochloride (HCl) — This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — unresectable advanced or metastatic ESCC
disease progression post a platinum-based chemotherapy
Must have received: immune checkpoint inhibitor — unresectable advanced or metastatic ESCC
disease progression post...an ICI treatment per global or local guidelines
Cannot have received: B7-H3 targeted agent (orlotamab, enoblituzumab, I-DXd)
prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd
Cannot have received: topoisomerase inhibitor
received any topoisomerase inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence Medical Foundation · Fullerton, California
- Henry Ford Health System · Detroit, Michigan
- Baptist Cancer Center · Memphis, Tennessee
- SCRI Oncology Partners · Nashville, Tennessee
- John Peter Smith Hospital · Fort Worth, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify